BOSTON, May 5, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the presentation of new data from a post hoc analysis of the Phase 1 ReCLAIM study evaluating elamipretide in patients with ...
BOSTON, April 28, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the company will have a poster presentation with a live discussion at the upcoming 2021 Association for Research in Vision ...
BOSTON, April 26, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will give the keynote presentation at the Mitochondria-Targeted Drug Development Digital Summit on ...
BOSTON, April 6, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the year ended December 31, 2020 and announced recent business highlights. "As we look forward to data from ...
BOSTON, March 31, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will report full year 2020 financial results on Tuesday, April 6, 2021, before the market opens. Management will host a ...
BOSTON, March 16, 2021 /PRNewswire/ -- Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced promotion of Marty Redmon, Ph.D., Executive Vice President, Discovery, Development, and Tech Ops, to the role of Chief Research & ...
BOSTON, March 2, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the following upcoming virtual investor conferences in March: H.C. Wainwright Global ...
BOSTON, Feb. 23, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the company completed enrollment for ReCLAIM-2 (SPIAM-202), and expects top-line data in the first half of 2022. ReCLAIM-2 ...
BOSTON, Feb. 10, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the purchase and sale of ...
BOSTON, Jan. 7, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will participate in pre-recorded presentations at the following virtual investor conferences in ...
media@stealthbt.com
